Here, we systematically investigated the expression, immune effects, and the influence of RBM47 on the clinical prognosis of patients with gliomas using clinical samples and RNA sequencing (RNA-seq) data from GSE4290, the China Glioma Genome Atlas (CGGA), The Cancer Genome Atlas (TCGA), CGGA single-cell sequencing data, and the GSE214966 and GSE131928 datasets. Here, RBM47 is linked to central nervous system cancer.